PHARMACOKINETIC AND CLINICAL EVALUATIONS OF FLUCONAZOLE IN PEDIATRIC PATIENTS

• Published in: Japanese journal of antibiotics Vol. 47; no. 3; pp. 296 - 303
• Main Authors: SUGITA, KUMIKO, MIYAKE, MUNENORI, TAKITANI, KIMITAKA, MURATA, TAKUJI, NISHIMURA, TADAFUMI, AOKI, SHIGEYUKI
• Format: Journal Article
• Language: Japanese
• Published: Japan Japan Antibiotics Research Association 01.03.1994
• Subjects: Administration, Oral; Candidiasis - drug therapy; Child; Child, Preschool; Female; Fluconazole - administration & dosage; Fluconazole - pharmacokinetics; Fluconazole - therapeutic use; Half-Life; Humans; Infant; Infant, Newborn; Injections, Intravenous; Male
• ISSN: 0368-2781; 2186-5477
• DOI: 10.11553/antibiotics1968b.47.296

Fluconazole (FLCZ) is a novel antifungal agent and available both in oral and intravenous forms. It is characterized by a long plasma half-life and a good absorbability into tissues. Because of these, it is expected to be used safety and to exhibit good clinical efficacy in the deep seated mycosis of children. We evaluated the efficacy of FLCZ given orally or intravenously to 6 patients. Pathogenic fungi isolated from all patients were Candida, and diagnosises made were candidemia in 3 cases, gastro-intestinal candidiasis in 2 and skin candidiasis. The clinical efficacies of FLCZ in 5 cases were excellent in 2 cases of gastro-intestinal candidiasis and poor in 3 cases of candidemia. None of the patients reported any side effect. In clinical laboratory tests, no abnormalities that were judged to be related to FLCZ were noted. In the study, clinical efficacy was shown to be poor in candidemia, because these cases had severe underlying diseases and the proper therapy was started too late. Thus earlier diagnosis and earlier treatment seem to be important for FLCZ to exhibit good clinical efficacy in the treatment of deep-seated mycosis.